top of page

Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in PTCL Presented at the Inaugural West German Lymphoma Symposium

Dublin, Ireland, June 4 2024 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, autoimmune and inflammatory diseases today announced that new pre-clinical data on the company’s first-in-class dual PIM/PI3K inhibitor, IBL-202, was highlighted in a poster presentation at the Inaugural West German Lymphoma Symposium which took place from May 24-25, 2024 in Essen, Germany. The pre-clinical data was generated through a collaboration between Inflection and the University Medical Center, Göttingen, Germany, led by PD Dr. med. Raphael Koch, Max-Eder Research Group Leader, Hematology and Oncology. The research evaluated the rationale for dual PIM and PI3K inhibition in peripheral T-cell lymphoma (PTCL). The collaboration was funded by Inflection Biosciences, University Medical Center, Göttingen, German Research Foundation (DFG), German Cancer Aid and Volkswagen Foundation. Dr. Raphael Koch commented “The data shows that the dual inhibition of PIM kinases and the PI3K/AKT pathway is a promising therapeutic strategy for PTCL. Moreover, a more pronounced G2/M cell cycle arrest was identified with IBL-202 versus AZD1208/Copanlisib combination, indicating mitotic catastrophe as a putative mechanism of cell death for IBL-202.” PTCL, a subtype of non-Hodgkin’s lymphoma, is as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. According to the World Health Organisation, the majority of PTCL subtypes have poor prognosis, with a 5-year overall survival of about 30%.

The poster abstract can be viewed here.

About Inflection Biosciences

Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. IBL-100s, partnered with Mysthera Therapeutics, is a pan-PIM kinase inhibitor program in preclinical development for the treatment of autoimmune diseases. AUM302, partnered with AUM Biosciences, is a first-in-class PIM/PI3K/mTOR inhibitor in development for the treatment of cancer. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia. For more information, please visit

For further information contact:

Inflection Biosciences Ltd

Darren Cunningham, Director

T: +353 (0)1 4003615


bottom of page